15.95 +0.02 (0.13%)
After hours: 6:11PM EDT
|Bid||15.93 x 800|
|Ask||16.00 x 4000|
|Day's Range||15.60 - 16.21|
|52 Week Range||14.59 - 25.96|
|Beta (3Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
The Oklahoma Supreme Court's decision was a win for the state's attorney general, whose case is set to be the first to face trial of roughly 2,000 lawsuits nationally seeking to hold opioid manufacturers responsible for contributing to the epidemic. Oklahoma Attorney General Mike Hunter's 2017 lawsuit accuses Purdue, Johnson & Johnson & Teva Pharmaceutical Industries Ltd of engaging in deceptive marketing that downplayed the risks of addiction associated with opioid pain drugs while overstating their benefits. The trial delay bid came as Purdue, owned by members of the wealthy Sackler family, was exploring filing for Chapter 11 bankruptcy protection to address potential liabilities stemming from the lawsuits, people familiar with the matter have told Reuters.
How Generic Pharmaceutical Stocks Are Positioned this MonthAnalysts’ recommendations and target prices Wall Street analysts expect an upside potential of 24.43% for Teva Pharmaceutical (TEVA), based on the company’s closing price on March 22. In
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S. Deferasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.
The trouble with value investing is that a pick that looks like a value stock could end up becoming a value trap.Source: Open Grid Scheduler (Modified)For example, Teva Pharmaceutical (NASDAQ: TEVA) is potentially a good turnaround play. TEVA hired a veteran CEO, Kare Schultz. It is cutting its debt and rolling out new products.One of Teva's biggest shareholders is Berkshire Hathaway (NYSE: BRK.A,BRK.B). After Berkshire bought TEVA stock, should you follow in its footsteps?InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 15 Stocks That May Be Hurt by This Year's Big IPOs The Good News About TEVA StockSince the fourth quarter, Teva has been addressing the ongoing shortage of EpiPen treatments. It is manufacturing more of the product and increasing its capacity to build more of it. EpiPen Jr., which has a dosage of 0.15 milligrams, compared to EpiPen's 0.3 milligrams, is scheduled to be released in the second quarter.On Feb. 4, Teva 's Ajovy migraine treatment was approved by the EU's pharmaceutical regulatory agency, the European Medicines Agency (EMA). Delivered via pre-filled syringes, each dose of Ajovy consists of 225 mg of an antibody that treats adults suffering from at least four migraines a month. It is a potential blockbuster.Migraine sufferers have few treatment options available, so getting Ajovy approved by the EMA would be a welcome development for the owners of Teva Pharmaceutical stock. Once the treatment is approved, TEVA needs to work on getting each country in the EU to agree to reimburse patients for it. Sales of Ajovy in the EU are expected to ramp up slowly over the next one or two years. Paying Down DebtTEVA expects to pay down $1.7 billion of its debt in July, using its operating cash flow and cash on hand. By avoiding both refinancing and re-negotiating its revolving credit facility, Teva could potentially lower the cost of maintaining its debt. The company is seeking to lower its net debt-to-EBITDA level to four by the end of next year. Copaxone Is a Headwind for TEVA StockFalling sales of the company's MS drug Copaxone, which lost its exclusivity, are a headwind to Teva's gross margins. Larger-than-expected gross margin declines, in turn, could weigh on TEVA stock. Opportunities Could Boost Teva Pharmaceutical StockAs mentioned earlier, gaining approval of Ajovy from the EU is a key component of Teva's turnaround plan. Getting health insurers and other payers to decide on the drug's accessibility and reimbursement details will have an impact on its success in the marketplace. In Q4, about 60% of U.S. commercial insurers covered the treatment.Generic Forteo, an injection treatment for osteoporosis, will start generating revenue for TEVA in the second half of this year. Its contribution will likely be slow at first. The product is not easy to make, and competitors will enter the market next year. Despite these challenges, TEVA is confident that the product will do well. Entering the Biosimilars MarketThrough its partnership with the hugely successful biotech firm, Regeneron Pharmaceuticals (NASDAQ: REGN), TEVA is building a pipeline of biosimilars and innovative biologics. Fasinumab, which interacts with the nerve-growth-factor protein and is supposed to treat osteoarthritis pain, met all of its endpoints in a recent trial, although data indicated that the treatment could increase the occurrence of rapidly progressing osteoarthritis.If Fasinumab, gets approved, it could be an option for doctors seeking a non-addictive pain therapy. At a time when opioid addiction has ruined so many lives, such a treatment option could help many patients. The Valuation of TEVA StockThe 13 analysts covering TEVA stock have an average price target of $19.76 on Teva Pharmaceutical stock (per Tipranks), versus the stock's level of $16.30 on Friday afternoon.Simply Wall ST estimates that the intrinsic value of TEVA stock, based on future cash flows, is $40. Those who buy Teva Pharmaceutical stock at its current level will be rewarded if TEVA stock rebound back to $40 in the next few years. The Bottom Line on TEVAValue investors cannot blindly follow Berkshire's investments, but they can evaluate Teva's potential on their own. At this point, the company's debt levels are frighteningly high. The prices and sales volumes of the company's new products may be weak in the short-term, potentially hurting its short-term results and weighing on TEVA stock.Still, Teva's CEO is highly qualified to lead the company's turnaround. Based on last quarter's numbers, TEVA appears to be heading in the right direction under his leadership.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy Today * 7 ETFs to Buy to Ride the Longevity Economy * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Compare Brokers The post After Berkshire Bought Teva Pharmaceutical Stock, Should Others Follow Suit? appeared first on InvestorPlace.
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Ten Years Gone A breeze had gently carried a slip of paper onto Broad Street. From where I did not know, but I did wonder. Somewhere else. Anywhere else. I had no idea why that slip of paper even caught my eye.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY
FDA Commissioner Scott Gottlieb is resigning from his post. During his tenure, generic drug approvals soared. The FDA also approved its first gene therapy under his administration.
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Growth drivers In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Comparing the tax rateIn its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for a non-GAAP adjusted tax rate of 10% for
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Free cash flow projections Bausch Health Companies (BHC) and Teva Pharmaceutical (TEVA) reported free cash flow of $1.27 billion and $1.79 billion, respectively,
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Expense guidance for fiscal 2018 In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) guided for adjusted non-GAAP SG&A
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector®1 Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. “The launch of our authorized generic of Flector® Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” said Brendan O’Grady, EVP and Head of North America Commercial.